Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • Log out
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Microenvironment and Immunology

Stromal Progenitor Cells from Endogenous Adipose Tissue Contribute to Pericytes and Adipocytes That Populate the Tumor Microenvironment

Yan Zhang, Alexes C. Daquinag, Felipe Amaya-Manzanares, Olga Sirin, Chieh Tseng and Mikhail G. Kolonin
Yan Zhang
Center for Stem Cell and Regenerative Medicine, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexes C. Daquinag
Center for Stem Cell and Regenerative Medicine, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felipe Amaya-Manzanares
Center for Stem Cell and Regenerative Medicine, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Sirin
Center for Stem Cell and Regenerative Medicine, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chieh Tseng
Center for Stem Cell and Regenerative Medicine, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mikhail G. Kolonin
Center for Stem Cell and Regenerative Medicine, Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/0008-5472.CAN-12-0294 Published October 2012
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Epidemiologic studies associate cancer with obesity, but the pathophysiologic connections remain obscure. In this study, we show that obesity facilitates tumor growth in mice irrespective of concurrent diet, suggesting a direct effect of excess white adipose tissue (WAT). When transplanted into mice, adipose stromal cells (ASC) can serve as perivascular adipocyte progenitors that promote tumor growth, perhaps helping explain the obesity–cancer link. In developing this hypothesis, we showed that ASCs are expanded in obesity and that they traffic from endogenous WAT to tumors in several mouse models of cancer. Strikingly, a comparison of circulating and tumor-infiltrating cell populations in lean, and obese mice revealed that cancer induces a six-fold increase of ASC frequency in the systemic circulation. We obtained evidence that ASCs mobilized in this way can be recruited into tumors, where they can be incorporated into blood vessels as pericytes and they can differentiate into adipocytes in an obesity-dependent manner. Extending this evidence, we found that increased tumor vascularization (reflected by changes in tumor vascular morphology and a two-fold increase in vascular density) was associated with intratumoral adipocytes and elevated proliferation of neighboring malignant cells. Taken together, our results suggest that ASCs recruited from endogenous adipose tissue can be recruited by tumors to potentiate the supportive properties of the tumor microenvironment. Cancer Res; 72(20); 5198–208. ©2012 AACR.

Introduction

Obesity involves abnormal accumulation of body fat. As a result of a prolonged positive energy balance, adipocytes in white adipose tissue (WAT) accumulate lipid droplets, which have systemic repercussions. Accompanying dyslipidemia, insulin resistance, and other systemic metabolic changes are important long-term consequences of obesity (1, 2). Epidemiology revealed that obesity, being a component of the metabolic syndrome, is associated with accelerated progression of several types of cancer (3, 4). The state of chronic inflammation ensuing in both cancer (5) and obesity (1) may play a key role in linking obesity and cancer (2). It has also been proposed that WAT has a direct effect on tumor growth (6, 7); however, convincing evidence has been lacking (8, 9). WAT is a potent endocrine organ secreting adipokines, such as cytokines and growth factors (1, 10). Leptin, insulin-like growth factors (IGF), and steroid hormones have been studied as adipokines potentially implicated in cancer (8–11). For example, IGF-1, systemic levels of which are elevated in obesity, is sufficient to accelerate tumor growth in cancer models (12).

While adipokines are secreted by adipocytes, important angiogenic, immunomodulatory, and survival factors are products of infiltrating monocytic cells and of perivascular adipocyte progenitors, termed adipose stromal cells (ASC; refs. 13–15). ASCs are similar to mesenchymal stromal cells (MSC) originally isolated as bone marrow colony-forming unit (CFU-F) fibroblasts (16, 17). Accumulating evidence indicates that MSCs serve as progenitors of cells contributing to the trophic tumor microenvironment (18–21). Administered bone marrow MSC and ASC engraft tumors in animal models result in accelerated cancer progression (7, 22–24); however, the physiologic relevance of these results has been unclear. The capacity of mesenchymal progenitors to sense cancer as a site of hypoxia/inflammation has been proposed to explain their tumor homing (17, 25). ASC proliferation accompanies WAT expansion (26) and number of ASCs per gram of WAT increases in obese individuals (27, 28). Mesenchymal progenitors are normally undetectable in the peripheral circulation; however, mobilization of cells with the ASC immunophenotype in obesity, further elevated in patients with cancer (29, 30), suggests the possibility of their trafficking. On the basis of these observations, we have reasoned that ASC mobilization and their recruitment by tumors could be increased in obesity, leading to increased stimulation of tumor growth through the paracrine action of adipokines.

To this day, the role of WAT in cancer progression has not been proven. Studies showing that tumor growth is accelerated by diet-induced obesity (DIO) have not successfully uncoupled effects of diet from effects of WAT (11, 31). Here, we show that excess WAT promotes tumor growth irrespective of the diet in mice. To investigate migration of cells from WAT during cancer progression, we used a competitive repopulation model that does not rely on invasive cell injections. We show that recruitment of endogenous ASCs in obesity is associated with increased vascularization and adipogenesis accompanied by proliferation of malignant cells.

Materials and Methods

Animal experiments

Mouse studies were carried out under the Animal Welfare Committee of the University of Texas (Houston, TX). Mouse strains C57BL/6, C57BL/6-Tg(UBC-GFP)30Scha/J (termed GFP mice), B6.Cg-Tg(ACTB-mRFP1)1F1Hadj/J (termed RFP mice), and B6.129S7-Rag1tm1Mom/J (termed RAG-1 mice) were from Jackson. For DIO induction (32), high-fat diet (HFD) D12492 (60 kcal% fat) and low-fat diet LFD (LFD) D12450B (10 kcal% fat) from Research Diets were used. Body composition was measured by EchoMRI-100T (Echo Medical Systems) as described (33). For tumor grafting, 106 cells were injected with a 21-gauge needle onto upper back (LLC and ID8) or into mammary fat pad (E0771 and MDA-231). Tumor size was measured with a caliper; volume was calculated as length × width2 × 0.52. Tissues were recovered from Avertin-anesthetized mice. Cells were isolated from tissues as described (7, 14).

Cell lines and primary cell culture

E0771 (from F.M. Sirotnak), ID8 (from F.C. Marini), and other cancer lines (from American Type Culture Collection) were cultured in Dulbecco's Modified Eagle's Media containing 10% FBS and authenticated by animal grafting and subsequent tumor histology. Blood was recovered by heart perfusion with 10 mL PBS/EDTA, and peripheral blood mononuclear cells (PBMC) were isolated as described (7, 30). Tissue suspensions were prepared as described (7, 14). Adipogenesis induction and Oil red O staining was conducted as described (14).

Flow cytometry

For fluorescence-activated cell sorting (FACS), cells were pregated to exclude debris, cell clumps, contaminating polymorphonuclear cells, red blood cells, as well as dead cells based on 7-aminoactinomycin D (7-AAD) staining. Tissue cell suspensions, WAT stromal/vascular fraction (SVF) with adipocytes removed (14), or PBMCs were sorted into populations with FACSAria/FACSDiva software (BD Biosciences) based on red fluorescent protein (RFP) fluorescence (Texas Red channel), GFP fluorescence [fluorescein isothiocyanate (FITC) channel], and the following IgG clones: APC-anti-CD34 (RAM34), PE-Cy7-anti-CD31 or PE-anti-CD31 (MEC 13.3), APC-Cy7-CD45 (30-F11), and the corresponding isotype controls (BD Biosciences). Isotypes and the positions of previously characterized hematopoietic and endothelial populations on the plots (7, 14) were used to set gate cutoffs.

Tissue analysis

Formalin-fixed, paraffin-embedded tissues were sectioned and analyzed by immunofluorescence as described (14). Primary antibodies used were goat anti-GFP (GeneTex, 1:100); rabbit anti-RFP (Abcam, 1:100); rabbit anti-Ki-67 (Thermo Scientific, 1:100); goat or rabbit anti-CD31 (Santa Cruz Biotechnology, 1:100); rabbit anti-desmin (Abcam, 1:200); and rabbit anti-perilipin (Cell Signaling Technology, 1:100). Secondary donkey Alexa 488–conjugated (1:150) IgG was from Invitrogen and Cy3-conjugated (1:300) IgG was from Jackson ImmunoResearch. Nuclei were stained with Hoechst 33258 or TO-PRO-3 (Invitrogen). Images were acquired with a confocal Leica TCS SP5 microscope/LAS AF software or Olympus IX70 inverted fluorescence microscope/MagnaFire software. For quantifications, at least 10 random ×100 magnification fields were blindly scored and/or measured using microscope grid.

Statistical analysis was conducted by using the one-tailed homoscedastic Student t test.

Results

Diet-independent effect of obesity on tumor growth

First, we wished to uncouple the direct effect of obesity on cancer progression from indirect effect of the diet. We set up cohorts by rendering mice obese (body mass > 45 g) or lean (body mass < 30 g) by prefeeding with HFD or LFD. To exclude diet as a variable, lean and obese mice have been placed on regular chow for 1 month before cancer initiation. HFD prefed mice slightly lost weight upon diet normalization, however, still had higher body mass due to increased body fat (Supplementary Fig. S1A and S1B). After diet normalization, mice were isografted with tumor cells. Obese mice displayed accelerated kinetics of Lewis lung carcinoma (LLC) growth, as compared with lean mice (Fig. 1A). As tumors grew in size, obese mice gradually lost weight, whereas lean mice maintained it (Fig. 1A). Fat, but not lean, body mass decreased in response to cancer (Supplementary Fig. S1B), indicating that weight loss was specifically due to the reduction in WAT amount. Human breast MDA-231 adenocarcinoma orthotopically xenografted into the mammary fat pad of RAG-1 mice also grew faster in DIO mice, although the effect was subtle, coincidentally with obesity being less pronounced in this strain (Supplementary Fig. S1C). Using an ovarian ID8 adenocarcinoma model, we segregated animals into obese, lean, and DIO-resistant mice that had become only moderately overweight on HFD before tumor implantation. Despite HFD prefeeding, the kinetics of tumor growth in DIO-resistant mice was not significantly different from that in the lean LFD controls (Supplementary Fig. S1C), indicating that prolonged positive energy balance does not fully account for the effect of obesity. Combined, these findings show that tumor growth can be promoted by obesity irrespective of diet at the time of tumor implantation and growth. Our data indicate excess WAT as an important component in the obesity–cancer relationship. However, the contribution of systemic physiologic obesity consequences, remaining post-diet normalization (34), cannot be excluded.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

ASC expansion and promoted tumor growth irrespective of diet in obesity. A, tumor growth in lean and obese (DIO) C57BL/6 mice grafted with LLC cells at week 0 upon diet normalization (left) and concomitant changes in body mass (right). B, flow cytometric enumeration of ASC (% of viable cells) among cells from i.p. WAT by gating SVF on viable CD31−CD45− cells and then on CD34+ cells. SSC-A, side scatter. C, relative net numbers of ASCs in i.p. WAT of lean and obese mice quantified on the basis of flow cytometric ASC frequency and total i.p. WAT mass. D, phase contrast micrograph of adherent India ink–stained cells from i.p. WAT after 1 day in culture featuring ASCs (arrowheads) and monocytes (arrows). E, adherent ASC recovery from i.p. WAT of obese mice normalized to lean mice (from equal WAT amount). F, enumeration of ASC as CD34+CD31−CD45− cells (% of viable) in PBMCs of lean and obese mice bearing tumors. G, micrographs of adherent CD34+CD31−CD45− cells sorted from WAT or from PBMCs of an obese mouse (left). H, oil red O staining of lipid droplets (arrows) in a colony formed by obese mouse PBMC–derived CD34+CD31−CD45− cell upon adipogenesis induction. Scale bar, 50 μm. Error bars, SEM. *, P < 0.05.

Obesity results in ASC expansion

We next set out to test whether recruitment of cells from excess WAT by tumors is implicated in obesity effect on cancer. Obese mice displayed a 7-fold increase in body fat amount (Supplementary Fig. S1B). To investigate accompanying ASC expansion, we compared ASC quantities in lean and obese animals. Unlike bone marrow MSCs, ASCs express CD34 (15), which enables their enumeration by flow cytometry as CD34+CD31−CD45− cells (7, 14). For intraperitoneal (i.p.) WAT, the major ASC reservoir (26), the ASC frequency was found to be 30.4% in lean and 32.6% in obese mice, respectively (Fig. 1B; Supplementary Fig. S2). On the basis of the total amounts of i.p. WAT recovered (1.0 ± 0.23 g from lean and 6.19 ± 0.25 g from obese mice), we calculated that the net number of i.p. ASCs is 6 times higher in obese mice (Fig. 1C). Frequencies of CD31−CD45−CD34+ cells were very low in the bone marrow, lungs, and liver of both lean and obese animals (Supplementary Fig. S2). Upon plating WAT stromal/vascular cells fraction, adherent ASCs appear as large fibroblasts with well-defined nuclei and nucleoli and can be clearly distinguished from smaller myelomonocytic cells internalizing India ink (Fig. 1D). Quantification of adherent ASCs from i.p. WAT upon enzymatic tissue digestion showed increased efficiency in their recovery from obese mice (Fig. 1E). Combined, these data indicate that WAT expanded in obesity serves as a reserve of extra ASCs.

Obesity-associated cell mobilization and tumor infiltration

To test whether ASCs traffic from WAT through the systemic circulation, we conducted a comparative analysis of PBMCs from lean and obese mice bearing tumors. Analysis of PBMCs (Supplementary Fig. S3A and S3B) showed that while circulating CD34+CD45− cells were rare in lean animals (0.06%), their frequency increased 6-fold (to 0.37%) in obesity (Fig. 1F). The majority of these cells had the CD34+CD31−CD45− ASC phenotype: the endothelial marker CD31 was expressed only by 5.9% of CD34+CD45− cells in obese mice (Supplementary Fig. S3A). Analysis of individual CD34+CD31−CD45− cells isolated by FACS showed morphology undistinguishable from that of ASCs sorted from WAT in parallel (Fig. 1G). Blood-derived CD34+CD31−CD45− cells formed colonies and accumulated lipid droplets upon adipogenic induction (Fig. 1H). The obesity-associated egress of CD34+CD31−CD45− adipocyte progenitors strongly suggests their ASC identity. To obtain evidence that ASCs may be recruited by tumors, we subjected tumor cell suspension to flow cytometric analysis. Indeed, tumors contained CD34+CD31−CD45− cells (Supplementary Fig. S2), and the increase in their frequency associated with obesity was consistent with their possible WAT origin.

A bone marrow transplantation model for tracking WAT-derived cells

To enable tracking of hematopoietic tumor stroma (17, 18, 35, 36) in parallel with ASCs, we designed an in vivo competitive repopulation assay. This obesity/cancer model is based on 2 syngeneic mouse strains: host ubiquitously expressing GFP and donor expressing RFP. In chimeric GFP/RFP mice generated through bone marrow transplantation (Fig. 2A), it is possible to distinguish hematopoietic (RFP+) from the host (GFP+) cells. We reasoned that, if ASC traffic in cancer as hypothesized, obesity should be associated with increased frequency of GFP+ cells in tumors. Upon DIO induction and RFP bone marrow transplantation followed by 1-month recovery on LFD and HFD, GFP/RFP chimeras were subjected to diet normalization and then orthotopically grafted into the mammary pad with E0771 cells, a line derived from syngeneic breast adenocarcinoma.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

In-parallel tracking of WAT and medullary cells. A, transplant scheme. Bone marrow from RFP (red) mice is transplanted into lethally irradiated lean or obese (DIO) GFP mice, which are grafted with tumors after diet normalization. In obese mice, trafficking of GFP+ ASCs (green) from WAT (yellow) is increased. B, GFP (green) and RFP (red) fluorescence of tissues and cells (1 day post-plating) isolated from an obese GFP/RFP chimera. Leukocytes (arrows) of host (green) and donor (red) origin and host ASCs (arrowheads) are indicated. C, flow cytometric enumeration of circulating GFP+ (FITC channel) cells among viable PBMCs from representative lean and obese E0771 tumor–grafted mice (left) and gating of the GFP+ cells from PBMCs of the obese mouse to enumerate CD34+ ASCs as a percentage of GFP+ cells (right). SSC-A, side scatter. D, total GFP+ cells from PBMCs of a lean and an obese mouse (C) were plated in culture for 1 day. GFP-fluorescent (green) adherent monocytes (arrows) and cells with the ASC morphology (arrowheads) are indicated. E, high magnification of obese mouse PBMC–derived GFP+ cells 4 days post-plating. F, lipid droplet formation (*) in a colony formed by an obese mouse PBMC–derived GFP+ cell ASCs 7 days after adipogenesis induction. Scale bar, 50 μm.

As expected, RFP+ and GFP+ cells were observed in all mouse tissues (Supplementary Fig. S4A and S4B). RFP+ cells were confirmed as CD45+ leukocytes, and less than 0.5% of bone marrow cells were GFP+ (Supplementary Fig. S4A). Femur sections revealed hematopoietic RFP+ cells relative to GFP+ vascular, bone, muscle, and WAT cells (Fig. 2B). Microscopic analysis of adherent WAT-derived cells showed the typical ASC morphology of GFP+ cells and RFP fluorescence of adherent leukocytes (Fig. 2B). In contrast, in peripheral blood, only rare adherent GFP+ cells were observed among RFP+ leukocytes (Fig. 2B). The majority of small adherent fibroblastoid RFP+ monocytes, also observed in no-color mice (Fig. 1D), were macrophages, as evident from India ink staining and F4/80 expression (Supplementary Fig. S3B).

Consistent with the data in no-color mice (Fig. 1F), we observed the frequency of circulating GFP+ cells being higher in obese mice (1.2%) than in lean mice (0.3%) by flow cytometry (Fig. 2C). In PBMCs of obese mice, 0.3% of GFP+ cells had the ASC CD34+CD31−CD45− immunophenotype, whereas the majority were CD45+ leukocytes (Fig. 2C). Adherent cell analysis confirmed that while in lean mice, virtually all circulating GFP+ cells had the monocytic appearance, larger GFP+ fibroblasts were present in PBMCs of obese mice (Fig. 2D). Their typical ASC appearance has become pronounced after 4 days in culture (Fig. 2E). Collagen-I, alpha-smooth muscle actin (α-SMA), and decorin, proteins expressed by ASCs (7, 14, 23) were expressed in colonies of GFP+CD34+CD31−CD45− cells (Supplementary Fig. S5). Accumulation of lipid droplets upon adipogenesis induction of the expanded GFP+CD34+CD31−CD45− cells as adipocyte progenitors (Fig. 2F) confirmed them as ASCs.

Engraftment of hematopoietic and WAT-derived cells in tumors

Tumors grew significantly faster in obese GFP/RFP chimeras concomitantly with fat mass loss (Fig. 3A). Confocal immunofluorescence on tumor sections (Fig. 3B) revealed that large GFP+ cells disseminated throughout both the peripheral and central tumor zones (Fig. 3B). They were observed at a higher frequency in obese mice, whereas RFP+ cell frequency showed the opposite trend (Supplementary Fig. S4B). Analysis of tumor cell suspensions in culture revealed adherent GFP+ cells with the ASC morphology (Fig. 3C). As expected, we also observed GFP+ and RFP+ monocytes (Fig. 3C). More adherent GFP+ cells were recovered from tumors grown in obese mice (Fig. 3D). Approximately 44% of adherent GFP+ tumor–derived cells had the ASC morphology in obese mice, compared with 23% in lean (Fig. 3E). To exclude tumor size as a confounder in assessing the effect of WAT excess on ASC numbers in tumors, we have taken advantage of gender-specific differences in tumor growth rate. Upon grafting E0771 tumors into chimeric GFP/RFP lean females and age-matched obese (HFD prefed) males, we observed comparable tumor growth curves in the 2 groups. Flow cytometry indicated that tumor GFP+ cell frequency was still higher in obese mice (9.8%) than in lean mice (3.0%), despite similar tumor size (Fig. 3F). Importantly, 20.0% of tumor GFP+ cells in lean mice and 30.1% in obese mice had the CD34+CD31−CD45− phenotype (Fig. 3F) indicating them as ASCs.

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Recruitment of ASCs by tumors increased in obesity. A, tumor growth in lean and obese GFP/RFP chimeras grafted with E0771 cells at week 0 upon diet normalization (left) and concomitant changes in fat body mass measured by EchoMRI (right). B, confocal immunofluorescence on sections from E0771 tumors with anti-GFP (green) and anti-RFP (red) antibodies identifies host and donor cells, respectively. Shown for lean and obese mice are peripheral and internal tumor areas as indicated. RFP+ cells within the stroma (red arrows), GFP+ cells within the stroma (green arrows), GFP+ vasculature-associated cells (green arrowheads), and tumor capsule (brackets) are indicated. Nuclei are stained with TO-PRO-3 (blue). C, adherent GFP+ cells with ASC morphology (arrowheads) and RFP+ monocytes (arrows) observed in culture 1 day post-plating of E0771 tumor cell suspension from an obese GFP/RFP chimera. D, adherent GFP+ cells FACS-sorted from E0771 tumors grown in lean and obese mice 1 day post-plating. Cells with ASC morphology (arrowheads) and other cell types (arrows) are indicated. E, percentages of cells with ASC morphology among GFP+ cells from D. F, flow cytometric analysis of cell suspensions from size-matched E0771 tumors grown in lean and obese mice. Viable cells were gated to separate RFP+ (Texas Red channel) and GFP+ (FITC channel) cells from malignant cells (blue). The combined GFP+ and RFP+ cells were then gated to visualize CD31+ and CD45+ cells. Finally, GFP+CD31−CD45− cells were gated to enumerate GFP+ cells with the ASC CD31−CD45−CD34+ phenotype (as a percentage of total GFP+ cells). *, P < 0.001. Error bar, SEM. Scale bar, 50 μm.

We tested whether a pericyte marker desmin could be used to further validate GFP+ cells as ASCs. Our data show that 91.3% of ASCs are indeed desmin-positive in WAT (Supplementary Fig. S6A). All PBMC CD34+CD31−CD45− cells and the majority (52.9%) of CD34+CD31−CD45− cells recovered from tumors also were desmin-positive (Supplementary Fig. S6A), suggesting that mobilized ASCs retain their pericyte identity. Four-color confocal immunofluorescence on tissue sections from GFP/RFP chimeras showed co-expression of CD34 and desmin on perivascular GFP+ cells in both WAT and in tumors (Supplementary Fig. S6B). Finally, immunoblotting revealed the presence of delta-decorin (ΔDCN), a recently identified marker of ASC (14), in tumor protein extracts (Supplementary Fig. S6C), confirming ASC recruitment by tumors.

Tumor vascularization and cell proliferation associated with ASC recruitment

Masson's trichrome staining revealed comparable deposition of collagen in tumors from lean and obese animals (Supplementary Fig. S7A). This analysis also revealed less extensive areas of hemorrhage and necrosis in obese mice. Immunofluorescence analysis revealed comparable fibronectin deposits typically devoid of GFP+ cells in tumors for each group (Supplementary Fig. S7B). These data show that the desmoplastic reorganization of the internal tumor matrix is not significantly influenced by obesity in the models used.

Blood vessels are essential for oxygen and nutrient delivery, and vascular patency predetermines tumor growth (35, 37). We therefore investigated whether ASC recruitment is associated with vascular remodeling. In obese mice, a higher proportion of endothelial cells were from the host, as revealed by luminal co-localization of CD31 with GFP (Fig. 4A and B). In lean mice, blood vessels were sparse in certain tumor areas, whereas in obese mice, they were abundant throughout the tumor mass (Fig. 4A). Quantification revealed a 2-fold higher vascular density in tumors from obese mice (Fig. 4C). Tumor vessels in lean mice were compressed and slim, whereas in obese mice, they were more hyperdilated (Fig. 4C) and filled with circulating blood cells (Fig. 4A and B). Enumeration of vessels positive for desmin+GFP+ cells (Fig. 4D) indicated a trend for increased vessels maturation in tumors from obese mice (Fig. 4C). In addition, expression of α-SMA, a perivascular marker expressed on ASCs (7, 14, 23), was more abundant on perivascular GFP+ cells in obese mice (Fig. 4E). Combined, these results reinforce the notion that ASCs contribute to the pool of perivascular cells in tumors in an obesity-dependent manner.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Pericyte recruitment in obesity and tumor vascularization. A and B, confocal immunofluorescence analysis of sections from E0771 tumors with anti-GFP (green) and anti-CD31 (red) antibodies. Shown for lean and obese GFP/RFP chimeras are internal tumor areas at low (A) and high (B) magnification. Blood vessels (red) contain luminal GFP+CD31+ endothelial cells (yellow arrows) and perivascular/stromal GFP+CD31− cells (green arrows). Note increased pericyte coverage and dilation of tumor vessels in obese mice. C, quantitative vasculature analysis in E0771 tumors from lean and obese mice. Vascular density was assessed as mean number of vessels per ×100 view field. Blood vessel size was assessed as mean lumen width for all vessels scored. Blood vessel maturity was assessed as mean percentage of vessels associated with desmin-positive pericytes among all vessels scored. Error bar, SEM. D, confocal immunofluorescence tumor analysis with anti-GFP (green) and anti-desmin (red) antibodies. Yellow signal upon digital channel merging indicates GFP+ pericytes, which is confirmed by Z-stack projections of median series for individual cells in the indicated magnified area (bottom). E, confocal immunofluorescence analysis of internal areas from E0771 tumors grown in lean and obese GFP/RFP chimeras with anti-GFP (green) and anti-α-SMA (red) antibodies. Nuclei are stained blue (TO-PRO-3). Scale bar, 100 μm.

An observation consistently made for tumors grown in obese animals was that tumor capsules were notably thicker than in lean mice (Figs. 3B and 5A and B). Tumor capsule composition also appeared different in obese animals (Supplementary Fig. S8A). Visually obvious increased adiposity was confirmed by immunofluorescence identifying perilipin, a marker of mature lipid droplets (Fig. 5A). Numerous large GFP+ cells were also observed dispersed throughout the tumor and contained unilocular perilipin-positive lipid droplets indicating them as adipocytes. While the presence of adipocytes at the tumor periphery could potentially be explainable by ingrowth of the surrounding connective tissue, the presence of separate adipocytes abundant within the tumor core indicates their differentiation from engrafting progenitors. Interestingly, the average size of adipocytes was notably larger in tumors grown in obese animals (Figs. 3 and 5), despite diet excluded as a variable.

Figure 5.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 5.

Adipogenesis and proliferation associated with tumor vascularization in obesity. A, analysis of sections from tumors by immunofluorescence with antibodies against GFP (green) and perilipin (red). a, GFP+ adipocytes containing perilipin+ unilocular lipid droplets; b, GFP+perilipin− blood vessels. B and C, analysis of sections from tumors with antibodies against GFP (green) and Ki-67 (red). Shown are proliferating tumor cells (arrowheads) and rare proliferating GFP+ cells (arrow). Shown are peripheral (A and B) and internal (C) E0771 tumor areas. Tumor capsule indicated with brackets. Scale bar, 100 μm. D, effect of proximity to clusters of intratumoral adipocytes (left) and to clusters of dilated blood vessels (right) on tumor cell proliferation. From 15 representative ×100 view fields, Ki-67+ nuclei were counted among 100 Hoechst 33258–stained nuclei. Shown are mean ± SEM. *, P < 0.05; ***, P < 0.001.

To test whether recruitment of ASCs is associated with changes in malignant cell proliferation, we conducted immunofluorescence analysis to detect Ki-67 (Supplementary Fig. S8B). Tumors in obese mice were found to contain comparatively more widespread areas populated with proliferating cells (Fig. 5B and C). Importantly, up to 10% of tumor cells were positive for Ki-67 in the vicinity of intratumoral adipocytes, as opposed to only 2% in areas devoid of adipocytes for obese mice (Fig. 5D). Cell proliferation was even more strikingly associated with the vasculature containing GFP+ cells (Fig. 5C). In obese mice, up to 30% of tumor cells were Ki-67+ next to large GFP+ blood vessels and less than 5% in poorly vascularized areas devoid of GFP+ cells (Fig. 5D). This trend was also observed for tumors in lean mice, although the frequency of tumor Ki-67+ cells was overall 4-fold lower (Fig. 5D). Because adipocytes themselves are found in association with blood vessels in tumors, at this point, it is unclear whether adipocytes support malignant cell proliferation and survival independently of the vasculature. Combined, our data from independent mouse models suggest that WAT excess leads to functional ASC engraftment in tumor stroma.

Discussion

Our results indicate that obesity can accelerate tumor growth irrespective of concurrent diet. While there are multiple systemic effects through which obesity may promote cancer (34), in this study, we focused on the potential role of excess WAT. We hypothesized that in addition to systemically secreting adipokines, WAT serves as a source of cells recruited by tumors and stimulating cancer through locally secreted paracrine factors. While bone marrow is the bona fide source of hematopoietic cells contributing to tumor microenvironment (18, 35, 36), our results indicate that mesenchymal progenitors are recruited to tumors, at least partly, from WAT. Evidence for this phenomenon has surfaced in other recent reports (7, 22–24, 38). However, preceding studies have been based on data from invasive nonphysiologic models. Here, we provide evidence for ASC trafficking from endogenous WAT in vivo.

Our data suggest that a combination of elevated ASC availability and their trafficking signaling results in the net increase of ASC recruitment to tumors in obesity. Our findings are consistent with the previously observed cellular tumor microenvironment composition changes in obesity (9, 39). The observed obesity-associated mobilization of ASCs, concomitant with their accumulation in tumor stroma/vasculature, indicates that WAT contributes to the pool of mesenchymal tumor cells. Our data argue against the possibility that proliferation of infiltrating ASCs significantly adds to their increased abundance in tumors. While it is likely that ASCs may infiltrate the tumor from adjacent surrounding WAT by migrating through solid tissues, recent reports on mobilization of mesenchymal progenitors in patients with cancer (29, 40) independently indicate the bloodstream as a contributing route. Our recent data suggest that CXCL1 and interleukin (IL)8 secreted by tumor cells and signaling via receptors CXCR1 or CXCR2 is implicated in migration of human omental ASCs (24), and future studies will establish the underlying mechanisms further.

The specific molecular pathways through which ASCs may contribute to cancer progression are yet to be established. Our data indicate that ASCs recruited by tumors become perivascular or differentiate into intratumoral adipocytes. Mesenchymal progenitors, including ASCs, had been previously shown to modulate cell survival, angiogenesis, and immune response (25), which could account for their tumor-promoting effects. While recent reports on tumor adipocytes in independent mouse models and in clinical specimens (41, 42) are in agreement with our findings, we have not observed accumulation of lipids in malignant cells reported in a recent study (43), which suggests that mechanisms of tumor lipid accumulation and metabolism may be cancer type–specific. Our data on obesity-associated increase in pericyte coverage of tumor vessels suggest increased vascular patency, resulting in increased malignant cell survival and proliferation, as a candidate mechanism of ASC effect. This possibility is consistent with reports on the pro-angiogenic effects of factors molecules secreted by ASCs (15, 44). On the basis of our combined data, we propose that increased adiposity and vascularization associated with obesity-associated ASC recruitment may be functional predeterminants of tumor cell survival and proliferation, both contributing to tumor growth (Fig. 6).

Figure 6.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 6.

A working model proposed for ASC trafficking in cancer. In addition to the bone marrow, WAT is a source of cells recruited by tumors. While tumor leukocytes are recruited mainly from the bone marrow, mesenchymal tumor stroma, pericytes, and adipocytes can be derived from ASCs migrating from WAT.

In summary, this study establishes recruitment of WAT-derived cells by tumors as a potential contributor to the stimulatory effects of obesity on cancer progression. We propose that several distinct ASC functions contribute to tumor growth induction observed in obesity. The apparent activity of WAT-derived cells in tumors raises a question about the safety of lipotransfer procedures in patients with cancer (45). Recent studies suggest the role of WAT-derived stroma in cancer metastasis (22), and development of approaches to targeted inactivation of ASCs will enable identification of their specific roles at distinct stages of cancer progression. We propose ASCs as a potential therapy target in cancer.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Authors' Contributions

Conception and design: M.G. Kolonin

Development of methodology: Y. Zhang, A.C. Daquinag, M.G. Kolonin

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): Y. Zhang, A.C. Daquinag, F. Amaya-Manzanares, O. Sirin, C. Tseng, M.G. Kolonin

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): Y. Zhang, A.C. Daquinag, F. Amaya-Manzanares, O. Sirin, C. Tseng, M.G. Kolonin

Writing, review, and/or revision of the manuscript: Y. Zhang, A.C. Daquinag, F. Amaya-Manzanares, O. Sirin, C. Tseng, M.G. Kolonin

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): Y. Zhang, F. Amaya-Manzanares, O. Sirin, C. Tseng, M.G. Kolonin

Study supervision: Y. Zhang, M.G. Kolonin

Grant Support

The work has been supported by grant CNE-119003 from the American Cancer Society, as well as grants RP100400 and RP110776 from the Cancer Prevention and Research Institute of Texas (CPRIT).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Acknowledgments

The authors thank M. Andreeff, Rolph Brekken, B.R. Davis, A.J. Marian, and P.J. Simmons for insightful comments as well as Fernando Florez for technical help.

Footnotes

  • Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

  • Received January 25, 2012.
  • Revision received August 13, 2012.
  • Accepted August 17, 2012.
  • ©2012 American Association for Cancer Research.

References

  1. 1.↵
    1. Park J,
    2. Euhus DM,
    3. Scherer PE
    . Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev 2011;32:550–70.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Cowey S,
    2. Hardy RW
    . The metabolic syndrome: a high-risk state for cancer? Am J Pathol 2006;169:1505–22.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Flegal KM,
    2. Graubard BI,
    3. Williamson DF,
    4. Gail MH
    . Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007;298:2028–37.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Calle EE,
    2. Kaaks R
    . Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579–91.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Coussens LM,
    2. Werb Z
    . Inflammation and cancer. Nature 2002;420:860–7.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Vona-Davis L,
    2. Howard-McNatt M,
    3. Rose DP
    . Adiposity, type 2 diabetes and the metabolic syndrome in breast cancer. Obes Rev 2007;8:395–408.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Zhang Y,
    2. Daquinag A,
    3. Traktuev DO,
    4. Amaya F,
    5. Simmons PJ,
    6. March KL,
    7. et al.
    White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res 2009;69:5259–66.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Roberts DL,
    2. Dive C,
    3. Renehan AG
    . Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010;61:301–16.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Khandekar MJ,
    2. Cohen P,
    3. Spiegelman BM
    . Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011;11:886–95.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Sirin O,
    2. Kolonin MG
    . Treatment of obesity as a potential complementary approach to cancer therapy. Drug Discov Today. 2012 May 22. [Epub ahead of print].
  11. 11.↵
    1. Grossmann ME,
    2. Ray A,
    3. Nkhata KJ,
    4. Malakhov DA,
    5. Rogozina OP,
    6. Dogan S,
    7. et al.
    Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev 2010;29:641–53.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Hursting SD,
    2. Nunez NP,
    3. Varticovski L,
    4. Vinson C
    . The obesity-cancer link: lessons learned from a fatless mouse. Cancer Res 2007;67:2391–3.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Traktuev D,
    2. Merfeld-Clauss S,
    3. Li J,
    4. Kolonin M,
    5. Arap W,
    6. Pasqualini R,
    7. et al.
    A Population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. Circ Res 2008;102:77–85.
    OpenUrlAbstract/FREE Full Text
  14. 14.↵
    1. Daquinag AC,
    2. Zhang Y,
    3. Amaya-Manzanares F,
    4. Simmons PJ,
    5. Kolonin MG
    . An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell 2011;9:74–86.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Gimble JM,
    2. Katz AJ,
    3. Bunnell BA
    . Adipose-derived stem cells for regenerative medicine. Circ Res 2007;100:1249–60.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Bianco P,
    2. Robey PG,
    3. Simmons PJ
    . Mesenchymal stem cells: revisiting history, concepts, and assays. Cell Stem Cell 2008;2:313–9.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Kolonin MG,
    2. Evans KW,
    3. Mani SA,
    4. Gomer RH
    . Alternative origins of stroma in normal organs and disease. Stem Cell Res 2012;8:312–23.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Chantrain CF,
    2. Feron O,
    3. Marbaix E,
    4. DeClerck YA
    . Bone marrow microenvironment and tumor progression. Cancer Microenviron 2008;1:23–35.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Galie M,
    2. Konstantinidou G,
    3. Peroni D,
    4. Scambi I,
    5. Marchini C,
    6. Lisi V,
    7. et al.
    Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene 2007;27:2542–5.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Karnoub AE,
    2. Dash AB,
    3. Vo AP,
    4. Sullivan A,
    5. Brooks MW,
    6. Bell GW,
    7. et al.
    Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557–63.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Bhowmick NA,
    2. Neilson EG,
    3. Moses HL
    . Stromal fibroblasts in cancer initiation and progression. Nature 2004;432:332–7.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Martin-Padura I,
    2. Gregato G,
    3. Marighetti P,
    4. Mancuso P,
    5. Calleri A,
    6. Corsini C,
    7. et al.
    The white adipose tissue used in lipotransfer procedures is a rich reservoir of CD34 +progenitors able to promote cancer progression. Cancer Res 2012;72:325–34.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Kidd S,
    2. Spaeth E,
    3. Watson K,
    4. Burks J,
    5. Lu H,
    6. Klopp A,
    7. et al.
    Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 2012;7:e30563.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Klopp AH,
    2. Zhang Y,
    3. Solley T,
    4. Amaya-Manzanares F,
    5. Marini F,
    6. Andreeff M,
    7. et al.
    Omental adipose tissue-derived stromal cells promote vascularization and growth of endometrial tumors. Clin Cancer Res 2012;18:771–82.
    OpenUrlAbstract/FREE Full Text
  25. 25.↵
    1. Bergfeld SA,
    2. DeClerck YA
    . Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 2010;29:249–61.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Joe AW,
    2. Yi L,
    3. Even Y,
    4. Vogl AW,
    5. Rossi FM
    . Depot-specific differences in adipogenic progenitor abundance and proliferative response to high-fat diet. Stem Cells 2009;27:2563–70.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Maumus M,
    2. Sengenes C,
    3. Decaunes P,
    4. Zakaroff-Girard A,
    5. Bourlier V,
    6. Lafontan M,
    7. et al.
    Evidence of in situ proliferation of adult adipose tissue-derived progenitor cells: influence of fat mass microenvironment and growth. J Clin Endocrinol Metab 2008;93:4098–106.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Daquinag AC,
    2. Zhang Y,
    3. Kolonin MG
    . Vascular targeting of adipose tissue as an anti-obesity approach. Trends Pharmacol Sci 2011;32:300–7.
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Bellows CF,
    2. Zhang Y,
    3. Chen J,
    4. Frazier ML,
    5. Kolonin MG
    . Circulation of progenitor cells in obese and lean colorectal cancer patients. Cancer Epidemiol Biomarkers Prev 2011;20:2461–8.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Bellows CF,
    2. Zhang Y,
    3. Simmons PJ,
    4. Khalsa AS,
    5. Kolonin MG
    . Influence of BMI on level of circulating progenitor cells. Obesity 2011;19:1722–6.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Nunez NP,
    2. Perkins SN,
    3. Smith NC,
    4. Berrigan D,
    5. Berendes DM,
    6. Varticovski L,
    7. et al.
    Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 2008;60:534–41.
    OpenUrlCrossRefPubMed
  32. 32.↵
    1. Kolonin MG,
    2. Saha PK,
    3. Chan L,
    4. Pasqualini R,
    5. Arap W
    . Reversal of obesity by targeted ablation of adipose tissue. Nat Med 2004;10:625–32.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Taicher GZ,
    2. Tinsley FC,
    3. Reiderman A,
    4. Heiman ML
    . Quantitative magnetic resonance (QMR) method for bone and whole-body-composition analysis. Anal Bioanal Chem 2003;377:990–1002.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. De Angel RE,
    2. Conti CJ,
    3. Wheatley KE,
    4. Brenner AJ,
    5. Otto G,
    6. Degraffenried LA,
    7. et al.
    The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog. 2012 Jan 30. doi: 10.1002/mc.21878. [Epub ahead of print].
  35. 35.↵
    1. Du R,
    2. Lu KV,
    3. Petritsch C,
    4. Liu P,
    5. Ganss R,
    6. Passegue E,
    7. et al.
    HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008;13:206–20.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Dawson MR,
    2. Chae SS,
    3. Jain RK,
    4. Duda DG
    . Direct evidence for lineage-dependent effects of bone marrow stromal cells on tumor progression. Am J Cancer Res 2011;1:144–54.
    OpenUrlPubMed
  37. 37.↵
    1. Hanahan D,
    2. Weinberg RA
    . Hallmarks of cancer: the next generation. Cell 2011;144:646–74.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Lin G,
    2. Yang R,
    3. Banie L,
    4. Wang G,
    5. Ning H,
    6. Li LC,
    7. et al.
    Effects of transplantation of adipose tissue-derived stem cells on prostate tumor. Prostate 2010;70:1066–73.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Park EJ,
    2. Lee JH,
    3. Yu GY,
    4. He G,
    5. Ali SR,
    6. Holzer RG,
    7. et al.
    Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010;140:197–208.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Mancuso P,
    2. Martin-Padura I,
    3. Calleri A,
    4. Marighetti P,
    5. Quarna J,
    6. Rabascio C,
    7. et al.
    Circulating perivascular progenitors: a target of PDGFR inhibition. Int J Cancer 2011;129:1344–50.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Dirat B,
    2. Bochet L,
    3. Dabek M,
    4. Daviaud D,
    5. Dauvillier S,
    6. Majed B,
    7. et al.
    Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 2011;71:2455–65.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Zyromski NJ,
    2. Mathur A,
    3. Pitt HA,
    4. Wade TE,
    5. Wang S,
    6. Nakshatri P,
    7. et al.
    Obesity potentiates the growth and dissemination of pancreatic cancer. Surgery 2009;146:258–63.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Nieman KM,
    2. Kenny HA,
    3. Penicka CV,
    4. Ladanyi A,
    5. Buell-Gutbrod R,
    6. Zillhardt MR,
    7. et al.
    Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011;17:1498–503.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Rehman J,
    2. Traktuev D,
    3. Li J,
    4. Merfeld-Clauss S,
    5. Temm-Grove CJ,
    6. Bovenkerk JE,
    7. et al.
    Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004;109:1292–8.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Bertolini F,
    2. Lohsiriwat V,
    3. Petit JY,
    4. Kolonin MG
    . Adipose tissue cells, lipotransfer and cancer: a challenge for scientists, oncologists and surgeons. Biochim Biophys Acta 2012;1826:209–14.
    OpenUrlPubMed
View Abstract
PreviousNext
Back to top
Cancer Research: 72 (20)
October 2012
Volume 72, Issue 20
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Stromal Progenitor Cells from Endogenous Adipose Tissue Contribute to Pericytes and Adipocytes That Populate the Tumor Microenvironment
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Stromal Progenitor Cells from Endogenous Adipose Tissue Contribute to Pericytes and Adipocytes That Populate the Tumor Microenvironment
Yan Zhang, Alexes C. Daquinag, Felipe Amaya-Manzanares, Olga Sirin, Chieh Tseng and Mikhail G. Kolonin
Cancer Res October 15 2012 (72) (20) 5198-5208; DOI: 10.1158/0008-5472.CAN-12-0294

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Stromal Progenitor Cells from Endogenous Adipose Tissue Contribute to Pericytes and Adipocytes That Populate the Tumor Microenvironment
Yan Zhang, Alexes C. Daquinag, Felipe Amaya-Manzanares, Olga Sirin, Chieh Tseng and Mikhail G. Kolonin
Cancer Res October 15 2012 (72) (20) 5198-5208; DOI: 10.1158/0008-5472.CAN-12-0294
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • TLR4-Mediated Inflammation Promotes Cellular Transformation
  • CD103 Signaling in Human TRM Cells
  • Expansion of Neoclonotypes and Anti–PD-1 Clinical Efficiency
Show more Microenvironment and Immunology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement